vs
Axsome Therapeutics, Inc.（AXSM）与Rocket Lab Corp（RKLB）财务数据对比。点击上方公司名可切换其他公司
Axsome Therapeutics, Inc.的季度营收约是Rocket Lab Corp的1.1倍（$196.0M vs $179.7M），Axsome Therapeutics, Inc.净利率更高（-14.6% vs -29.5%，领先14.9%），Axsome Therapeutics, Inc.同比增速更快（65.0% vs 35.7%），Axsome Therapeutics, Inc.自由现金流更多（$-18.7M vs $-114.2M），过去两年Axsome Therapeutics, Inc.的营收复合增速更高（61.7% vs 39.2%）
Jazz Pharmaceuticals是一家全球生物制药企业，专注于肿瘤学与神经科学领域的药物研发及商业化。公司2003年在美国加利福尼亚州成立，目前总部位于爱尔兰都柏林，业务覆盖全球多个核心市场。
Rocket Lab是公开上市的航空航天制造商及发射服务提供商，旗下Electron轨道火箭主打小型卫星发射，截至2026年1月已成功完成超75次任务，是全球现役发射次数最多的小型运载火箭。公司还开发了Electron的亚轨道改型HASTE用作高超音速技术测试平台，下一代可复用中型运载火箭Neutron目前也在研发中。
AXSM vs RKLB — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $196.0M | $179.7M |
| 净利润 | $-28.6M | $-52.9M |
| 毛利率 | — | 38.0% |
| 营业利润率 | -13.8% | -28.4% |
| 净利率 | -14.6% | -29.5% |
| 营收同比 | 65.0% | 35.7% |
| 净利润同比 | 61.9% | -1.1% |
| 每股收益（稀释后） | $-0.55 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $196.0M | $179.7M | ||
| Q3 25 | $171.0M | $155.1M | ||
| Q2 25 | $150.0M | $144.5M | ||
| Q1 25 | $121.5M | $122.6M | ||
| Q4 24 | $118.8M | $132.4M | ||
| Q3 24 | $104.8M | $104.8M | ||
| Q2 24 | $87.2M | $106.3M | ||
| Q1 24 | $75.0M | $92.8M |
| Q4 25 | $-28.6M | $-52.9M | ||
| Q3 25 | $-47.2M | $-18.3M | ||
| Q2 25 | $-48.0M | $-66.4M | ||
| Q1 25 | $-59.4M | $-60.6M | ||
| Q4 24 | $-74.9M | $-52.3M | ||
| Q3 24 | $-64.6M | $-51.9M | ||
| Q2 24 | $-79.3M | $-41.6M | ||
| Q1 24 | $-68.4M | $-44.3M |
| Q4 25 | — | 38.0% | ||
| Q3 25 | — | 37.0% | ||
| Q2 25 | — | 32.1% | ||
| Q1 25 | — | 28.8% | ||
| Q4 24 | — | 27.8% | ||
| Q3 24 | — | 26.7% | ||
| Q2 24 | — | 25.6% | ||
| Q1 24 | — | 26.1% |
| Q4 25 | -13.8% | -28.4% | ||
| Q3 25 | -27.0% | -38.0% | ||
| Q2 25 | -24.5% | -41.3% | ||
| Q1 25 | -46.9% | -48.3% | ||
| Q4 24 | -61.1% | -38.9% | ||
| Q3 24 | -59.8% | -49.5% | ||
| Q2 24 | -89.5% | -40.7% | ||
| Q1 24 | -89.7% | -46.4% |
| Q4 25 | -14.6% | -29.5% | ||
| Q3 25 | -27.6% | -11.8% | ||
| Q2 25 | -32.0% | -46.0% | ||
| Q1 25 | -48.9% | -49.5% | ||
| Q4 24 | -63.1% | -39.5% | ||
| Q3 24 | -61.7% | -49.6% | ||
| Q2 24 | -91.0% | -39.2% | ||
| Q1 24 | -91.1% | -47.7% |
| Q4 25 | $-0.55 | $-0.09 | ||
| Q3 25 | $-0.94 | $-0.03 | ||
| Q2 25 | $-0.97 | $-0.13 | ||
| Q1 25 | $-1.22 | $-0.12 | ||
| Q4 24 | $-1.54 | $-0.11 | ||
| Q3 24 | $-1.34 | $-0.10 | ||
| Q2 24 | $-1.67 | $-0.08 | ||
| Q1 24 | $-1.44 | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $322.9M | $1.0B |
| 总债务越低越好 | — | $152.4M |
| 股东权益账面价值 | $88.3M | $1.7B |
| 总资产 | $689.8M | $2.3B |
| 负债/权益比越低杠杆越低 | — | 0.09× |
8季度趋势，按日历期对齐
| Q4 25 | $322.9M | $1.0B | ||
| Q3 25 | $325.3M | $976.7M | ||
| Q2 25 | $303.0M | $688.1M | ||
| Q1 25 | $300.9M | $428.4M | ||
| Q4 24 | $315.4M | $419.0M | ||
| Q3 24 | $327.3M | $442.4M | ||
| Q2 24 | $315.7M | $496.8M | ||
| Q1 24 | $331.4M | $492.5M |
| Q4 25 | — | $152.4M | ||
| Q3 25 | — | $347.0M | ||
| Q2 25 | — | $346.5M | ||
| Q1 25 | — | $345.9M | ||
| Q4 24 | — | $345.4M | ||
| Q3 24 | — | $61.2M | ||
| Q2 24 | — | $64.2M | ||
| Q1 24 | — | $66.8M |
| Q4 25 | $88.3M | $1.7B | ||
| Q3 25 | $73.7M | $1.3B | ||
| Q2 25 | $73.1M | $688.5M | ||
| Q1 25 | $53.2M | $431.3M | ||
| Q4 24 | $57.0M | $382.5M | ||
| Q3 24 | $92.9M | $419.8M | ||
| Q2 24 | $102.9M | $455.2M | ||
| Q1 24 | $144.0M | $478.9M |
| Q4 25 | $689.8M | $2.3B | ||
| Q3 25 | $669.3M | $2.2B | ||
| Q2 25 | $639.8M | $1.6B | ||
| Q1 25 | $596.7M | $1.3B | ||
| Q4 24 | $568.5M | $1.2B | ||
| Q3 24 | $561.5M | $1.2B | ||
| Q2 24 | $548.2M | $1.2B | ||
| Q1 24 | $545.7M | $1.2B |
| Q4 25 | — | 0.09× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.50× | ||
| Q1 25 | — | 0.80× | ||
| Q4 24 | — | 0.90× | ||
| Q3 24 | — | 0.15× | ||
| Q2 24 | — | 0.14× | ||
| Q1 24 | — | 0.14× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-18.7M | $-64.5M |
| 自由现金流经营现金流 - 资本支出 | $-18.7M | $-114.2M |
| 自由现金流率自由现金流/营收 | -9.6% | -63.6% |
| 资本支出强度资本支出/营收 | 0.0% | 27.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-93.9M | $-321.8M |
8季度趋势，按日历期对齐
| Q4 25 | $-18.7M | $-64.5M | ||
| Q3 25 | $1.0M | $-23.5M | ||
| Q2 25 | $-32.4M | $-23.2M | ||
| Q1 25 | $-43.4M | $-54.2M | ||
| Q4 24 | $-26.2M | $-2.4M | ||
| Q3 24 | $-18.6M | $-30.9M | ||
| Q2 24 | $-30.1M | $-13.0M | ||
| Q1 24 | $-53.5M | $-2.6M |
| Q4 25 | $-18.7M | $-114.2M | ||
| Q3 25 | $988.0K | $-69.4M | ||
| Q2 25 | $-32.4M | $-55.3M | ||
| Q1 25 | $-43.7M | $-82.9M | ||
| Q4 24 | $-26.2M | $-23.9M | ||
| Q3 24 | $-18.7M | $-41.9M | ||
| Q2 24 | $-30.2M | $-28.3M | ||
| Q1 24 | $-53.6M | $-21.8M |
| Q4 25 | -9.6% | -63.6% | ||
| Q3 25 | 0.6% | -44.8% | ||
| Q2 25 | -21.6% | -38.3% | ||
| Q1 25 | -36.0% | -67.6% | ||
| Q4 24 | -22.1% | -18.1% | ||
| Q3 24 | -17.9% | -40.0% | ||
| Q2 24 | -34.6% | -26.7% | ||
| Q1 24 | -71.4% | -23.5% |
| Q4 25 | 0.0% | 27.6% | ||
| Q3 25 | 0.0% | 29.6% | ||
| Q2 25 | 0.0% | 22.2% | ||
| Q1 25 | 0.3% | 23.4% | ||
| Q4 24 | 0.0% | 16.3% | ||
| Q3 24 | 0.1% | 10.5% | ||
| Q2 24 | 0.1% | 14.4% | ||
| Q1 24 | 0.1% | 20.7% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AXSM
暂无分部数据
RKLB
| Products | $94.0M | 52% |
| Transferred Over Time | $87.3M | 49% |
